Morphotek and GlaxoSmithKline enter into multi-project collaboration

Under the agreement, Morphotek’s proprietary Morphodoma technology will be applied to GSK’s antibody producer lines to generate the cell lines. Morphotek will receive funding to support R&D efforts for an initial project to be performed for GSK, with the option for GSK to retain Morphotek for two additional projects.

Morphotek may also receive annual licensing fees and milestone payments upon the successful achievement of project goals and the advancement of the resultant products through clinical development. GSK will conduct the preclinical and clinical development and subsequent commercialization of all products.

Commenting on the agreement, Mike Owen, senior vice president of the GSK Biopharm Centre of Excellence for Drug Discovery, said, “This exciting collaboration with Morphotek is a further demonstration of GSK’s commitment to establish a leading position in the biopharmaceutical market. We look forward to developing a strong collaboration with the team at Morphotek.”